TrialSignal transduction and targeted therapy2025

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial.

Guoshuang Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.